Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Osteosarcoma 1NSCLC 1Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

Gefitinib 5icotinib 4Pemetrexed 4Docetaxel 4camrelizumab 3apatinib 3anlotinib 3aflutinib 3Erlotinib Hydrochloride 3osimertinib 2dacomitinib 2Thalidomide 2Radiosurgery 2Drug Therapy 2Carboplatin 2Afatinib 2trilaciclib 1spartalizumab 1pembrolizumab 1nimotuzumab 1famitinib 1envafolimab 1Vinorelbine 1Tyrosine Kinase Inhibitors 1S 1 (combination) 1Radiofrequency Ablation 1Microphysiological Systems 1Immune Checkpoint Inhibitors 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × NSCLC × trilaciclib × Clear all
NCT06328049 2024-03-25

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Taixing People's Hospital

Phase 2 Unknown
30 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡